Karine Tawagi MD (@drkarinetawagi) 's Twitter Profile
Karine Tawagi MD

@drkarinetawagi

GU Oncologist | APD | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast

ID: 1112755822113841153

calendar_today01-04-2019 16:37:16

629 Tweet

1,1K Followers

1,1K Following

TwoOncDocs (@twooncdocs) 's Twitter Profile Photo

Part 2 melanoma with the expert Dr. Mike Atkins this week discussing: The Aha moment when he saw IO changing the landscape 🌟 When to use LAG3 combo DREAMseq IO vs BRAF for which he was 1st author 🌟 Oligometastatic dx Uveal / mucosal melanoma Career tips #meded

Part 2 melanoma with the expert Dr. Mike Atkins this week discussing:

The Aha moment when he saw IO changing the landscape 🌟
When to use LAG3 combo 
DREAMseq IO vs BRAF for which he was 1st author 🌟
Oligometastatic dx
Uveal / mucosal melanoma
Career tips

#meded
Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Have spent a lot of time thinking about the #CLEAR & #KN426 biomarker presentations at #ASCO24 by Toni Choueiri, MD & Brian Rini, MD. Huge efforts & grateful that investment was made in this work. Could the differences observed in the association of immune signatures with outcome lend

Have spent a lot of time thinking about the #CLEAR &amp; #KN426 biomarker presentations at #ASCO24 by <a href="/DrChoueiri/">Toni Choueiri, MD</a> &amp; <a href="/brian_rini/">Brian Rini, MD</a>. Huge efforts &amp; grateful that investment was made in this work. Could the differences observed in the association of immune signatures with outcome lend
TwoOncDocs (@twooncdocs) 's Twitter Profile Photo

We released an update on our most listened episode topic - AML - w/ a special guest Dr. Catherine Lai from U Penn! In Part 1 we discuss the presentation, diagnostic work-up, and updates on the classification of AMLs, as well as tips to remember them 🩸

We released an update on our most listened episode topic - AML - w/ a special guest <a href="/KatieLaiMD_MPH/">Dr. Catherine Lai</a> from U Penn! 

In Part 1 we discuss the presentation, diagnostic work-up, and updates on the classification of AMLs, as well as tips to remember them 🩸
Tom Powles (@tompowles1) 's Twitter Profile Photo

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had  a statistically significant and clinically meaningful improvement in EFS &amp; OS versus chemo/cystectomy  alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…
Alan Tan (@alantanmd) 's Twitter Profile Photo

Please consider enrolling at your institution. Matt Galsky and I discuss the importance of the @AllianceNCTN A032103 MODERN study, a ctDNA 🧬 informed approach to adjuvant bladder cancer therapy. MRD+ patients get PD1 or PD1/LAG3 Bladder Cancer Advocacy Network Jonathan Rosenberg MD Andrea Apolo, M.D.

Tom Powles (@tompowles1) 's Twitter Profile Photo

Asked to predict the future of advanced bladder cancer post neoadjuvant therapy #GUARDSymposium2024 Enrique Grande points out my tack record of predicting the future is not that great,l.

Asked to predict the future of advanced bladder cancer post neoadjuvant therapy #GUARDSymposium2024 <a href="/drenriquegrande/">Enrique Grande</a> points out my tack record of predicting the future is not that great,l.
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

Updated National Comprehensive Cancer Network (NCCN) guidelines (1.2025) are in, with some major changes for systemic therapies: 1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC 2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC 3) Adjuvant Pembro is now Category 1 KidneyCAN

Updated <a href="/NCCN/">National Comprehensive Cancer Network (NCCN)</a> guidelines (1.2025) are in, with some major changes for systemic therapies:
1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC  2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC  
3) Adjuvant Pembro is now Category 1 

<a href="/kidneycan/">KidneyCAN</a>
Tom Powles (@tompowles1) 's Twitter Profile Photo

More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivo showed no ⬆️ in efficacy v.s Tivo alone in PD(L)1 pretreated RCC pts. ⬇️ Tivo dose in study arm requires consideration. This has implications post adjuvant pembro prnewswire.com/news-releases/…

Karine Tawagi MD (@drkarinetawagi) 's Twitter Profile Photo

Opportunities for 🚬 cessation by Dr. Bjurlin at #BCANthinktank Bladder Cancer Advocacy Network 🟧 only ~20% of pts knew smoking RF for BCa 🟨 1/3 of all visits with urologists are for tobacco-related disease 🟧 active smokers 3x more likely to die of BCa then former smokers

Opportunities for 🚬 cessation by Dr. Bjurlin at #BCANthinktank <a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> 

🟧 only ~20% of pts knew smoking RF for BCa 
🟨 1/3 of all visits with urologists are for tobacco-related disease
🟧 active smokers 3x more likely to die of BCa then former smokers
Karine Tawagi MD (@drkarinetawagi) 's Twitter Profile Photo

2015 vs 2024 National Comprehensive Cancer Network (NCCN) guidelines for Advanced Bladder Cancer Remarkable how far we have come in 10 years as we have improved our treatment options for better patient outcomes in BCa 🧡Bladder Cancer Advocacy Network #BCANTT24

2015 vs 2024 <a href="/NCCN/">National Comprehensive Cancer Network (NCCN)</a> guidelines for Advanced Bladder Cancer

Remarkable how far we have come in 10 years as we have improved our treatment options for better patient outcomes in BCa 

🧡<a href="/BladderCancerUS/">Bladder Cancer Advocacy Network</a> #BCANTT24
Karine Tawagi MD (@drkarinetawagi) 's Twitter Profile Photo

Expert panel #BCANTT24 on the future of IO in BCa: 🟨 key ongoing trials w/ recent NIAGARA read-out 🟧 lack biomarkers of response & resistance, PDL1 is not it  ➡️ need de-escalation as many pt advocates expressed this meeting  ❓inc consolidation for CR in mUC, IO post IO

Expert panel #BCANTT24 on the future of IO in BCa:
🟨 key ongoing trials w/ recent NIAGARA read-out
🟧 lack biomarkers of response &amp; resistance, PDL1 is not it 
➡️ need de-escalation as many pt advocates expressed this meeting 
❓inc consolidation for CR in mUC, IO post IO
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

1/ Results from #LITESPARK-005 are out <a href="/NEJM/">NEJM</a>! 
The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) <a href="/US_FDA/">U.S. FDA</a> approval Dec 2023 in pretreated pts w/ #ccRCC. 
Presentation #ESMO24 @myEsmo

Check it out: nejm.org/doi/full/10.10…
Tom Powles (@tompowles1) 's Twitter Profile Photo

Belzutifan significantly outperformed everolimus in heavily pretreated clear cell renal cancer. Toni Choueiri, MD Brian Rini, MD Laurence Albiges ⬆️ RR, PFS, QOL but no OS. Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited

Belzutifan significantly outperformed everolimus in heavily pretreated clear cell renal cancer. <a href="/DrChoueiri/">Toni Choueiri, MD</a> <a href="/brian_rini/">Brian Rini, MD</a> <a href="/AlbigesL/">Laurence Albiges</a> ⬆️ RR, PFS, QOL but no OS. Data suggests belzutifan is better in less heavily treated disease and in combination. 1st line and adjuvant trials awaited
Ronac Mamtani (@ron_cology) 's Twitter Profile Photo

We've had no data on real-world EV+P use for mUC, until now. In European Urology we show rapid dissemination of EV+P in practice. As of 3/31/24, <4 mo after U.S. FDA full approval, EV+P accounted for ~50% of 1L tx starts, supplanting platinum-chemo (23%). authors.elsevier.com/a/1jeFg14kplyy…

We've had no data on real-world EV+P use for mUC, until now. In <a href="/EUplatinum/">European Urology</a> we show rapid dissemination of EV+P in practice. As of 3/31/24, &lt;4 mo after <a href="/US_FDA/">U.S. FDA</a> full approval, EV+P accounted for ~50% of 1L tx starts, supplanting platinum-chemo (23%). 
authors.elsevier.com/a/1jeFg14kplyy…
Tian Zhang, MD, MHS (@tiansterzhang) 's Twitter Profile Photo

T -3 weeks til #ESMO24! Presidential plenaries are online — ⭐️ 9/14 silke gillessen #PEACE3 radium-enza vs enza in #prostatecancer ⭐️ 9/15 Tom Powles #NIAGARA durva-chemo in #bladdercancer, discussed by Petros Grivas! See you in Barcelona! #ESMOAmbassadors ESMO - Eur. Oncology OncoAlert

TwoOncDocs (@twooncdocs) 's Twitter Profile Photo

We just released a new episode w/ Dr. Janet Abrahm from Dana-Farber, a national leader in palliative care, impt for any specialty! We cover: 🌟how to explain pall care to pts 🌟pain & anti-emetic management 🌟non-pharmacologic strategies 🌟innovations podcasts.apple.com/us/podcast/two…

We just released a new episode w/ Dr. Janet Abrahm from <a href="/DanaFarber/">Dana-Farber</a>, a national leader in palliative care, impt for any specialty! 

We cover:
🌟how to explain pall care to pts
🌟pain &amp; anti-emetic management
🌟non-pharmacologic strategies 
🌟innovations

podcasts.apple.com/us/podcast/two…
Alan Tan (@alantanmd) 's Twitter Profile Photo

The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or Brian Rini, MD to inquire further. We will also be at #ESMO24

The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding.  We are seeking a GU medical oncology clinical investigator to join our innovative team.  Please message me or <a href="/brian_rini/">Brian Rini, MD</a> to inquire further.  We will also be at #ESMO24